Welcome to our dedicated page for Cerevel Therapeutics Holdings news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Holdings stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). Formed in 2018 through a partnership between Bain Capital and Pfizer, Cerevel is headquartered in Cambridge, Massachusetts. The company is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases using a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity.
Cerevel's pipeline includes five clinical-stage investigational therapies and several preclinical compounds targeting a range of CNS disorders, such as Parkinson’s disease, Alzheimer’s disease psychosis, epilepsy, schizophrenia, and addiction. The company’s lead programs include:
- Emraclidine: An M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer’s disease psychosis.
- Darigabat: An α2/3/5-selective GABAA receptor PAM currently under development for epilepsy and panic disorder.
- Tavapadon: A D1/D5 partial agonist currently in Phase 3 for the treatment of Parkinson’s disease.
- CVL-871: A D1/D5 partial agonist in development for treatment of dementia-related apathy.
In recent news, Cerevel announced the pricing of its underwritten public offering, where it successfully raised approximately $450 million. Additionally, Cerevel reported positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon as an adjunctive therapy to levodopa in Parkinson’s disease. The company is also advancing its early clinical pipeline and discovery programs while exploring new modalities through internal research, external collaborations, or potential acquisitions.
On December 6, 2023, Cerevel announced its acquisition by AbbVie Inc. (NYSE: ABBV). The transaction, valued at approximately $8.7 billion, aims to bolster AbbVie’s neuroscience portfolio with Cerevel’s robust pipeline of therapies. The acquisition is expected to close by mid-2024, subject to regulatory approvals and other customary conditions.
Cerevel continues to drive forward with its mission, leveraging its deep understanding of neurocircuitry and targeted receptor subtype selectivity to develop innovative treatments for neuroscience diseases, ultimately aiming to improve patient outcomes and quality of life.
AbbVie (NYSE: ABBV) has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE), strengthening its neuroscience portfolio. The acquisition brings multiple clinical-stage assets, including emraclidine, a potential best-in-class antipsychotic for schizophrenia, and tavapadon, a first-in-class treatment for Parkinson's disease. AbbVie expects the acquisition to be accretive to adjusted diluted EPS beginning in 2030.
The company reaffirms its 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91, which includes a $0.19 per share dilutive impact from the Cerevel acquisition. AbbVie also maintains its third-quarter adjusted diluted EPS guidance range of $2.92-$2.96. The acquisition is expected to contribute to AbbVie's long-term performance and complement its existing neuroscience pipeline.
On May 24, 2024, leading law firm Bleichmar Fonti & Auld LLP (BFA) announced an investigation into the merger between Cerevel Therapeutics (Nasdaq: CERE) and AbbVie. The acquisition deal, valued at $8.7 billion, will see AbbVie purchasing all outstanding Cerevel shares at $45 per share in cash. The boards of both companies have approved the transaction, which is expected to close mid-2024.
BFA is investigating claims that Cerevel's board was conflicted and engaged in an unfair process, potentially undervaluing the shares. Shareholders are encouraged to seek more information about their legal options through BFA's dedicated webpage. Representation is offered on a contingency basis, meaning shareholders incur no costs unless a recovery is made.
Bleichmar Fonti & Auld LLP (BFA) is investigating the merger between Cerevel Therapeutics Holdings and AbbVie, announced on December 6, 2023. AbbVie will acquire all outstanding shares of Cerevel for $45 per share in cash, valuing Cerevel at approximately $8.7 billion. The transaction has been approved by the boards of both companies and is expected to close in mid-2024. BFA is probing into potential conflicts of interest and unfair processes in the decision-making that could have led to an undervaluation of Cerevel’s shares. Shareholders of Cerevel are encouraged to seek legal advice and explore their options.
BFA LLP has announced an investigation into the merger between Cerevel Therapeutics (NASDAQ: CERE) and AbbVie. Under the merger terms, AbbVie will buy all outstanding shares of Cerevel for $45.00 per share in cash, valuing the company at approximately $8.7 billion. This transaction, approved by the boards of directors of both companies, is set to close in mid-2024. BFA LLP suspects that Cerevel's board was conflicted and agreed to an unfair price for shareholders. Shareholders may have legal options and can obtain more information or legal representation on a contingency fee basis by visiting BFA's website or contacting them directly.
FAQ
What is the current stock price of Cerevel Therapeutics Holdings (CERE)?
What is the market cap of Cerevel Therapeutics Holdings (CERE)?
What does Cerevel Therapeutics Holdings, Inc. specialize in?
When was Cerevel Therapeutics formed?
Where is Cerevel Therapeutics headquartered?
What are some of Cerevel Therapeutics' leading investigational therapies?
What is the significance of Cerevel’s recent Phase 3 TEMPO-3 trial results?
What recent financial achievement has Cerevel accomplished?
What major acquisition was announced involving Cerevel Therapeutics?
What is the expected closing date for the AbbVie acquisition of Cerevel?
What is Cerevel Therapeutics' approach to treating neuroscience diseases?
Who are the contacts for media and investor inquiries at Cerevel Therapeutics?
